I-Mab Reports Dosing of TJ202/MOR202 in P-II Trial for Patients with Relapsed or Refractory Multiple Myeloma

 I-Mab Reports Dosing of TJ202/MOR202 in P-II Trial for Patients with Relapsed or Refractory Multiple Myeloma

I-Mab Reports Dosing of TJ202/MOR202 in P-II Trial for Patients with Relapsed or Refractory Multiple Myeloma

Shots:

  • The first P-II NCT03860038 trial involves assessing of TJ202/MOR202 as a 3L treatment in patients with R/R MM while the second P-II trial assess TJ202/MOR202 + lenalidomide (LEN) + dexamethasone (DEX) vs LEN + DEX in 1L R/R MM
  • In 2017, I-Mab in-licensed TJ202/MOR202 from MorphoSys while holds exclusive rights to develop and commercialize it in Mainland China, Hong Kong, Macao and Taiwan and is targeting the candidate in multiple myeloma and in certain autoimmune diseases, including systemic lupus erythematosus
  • TJ202/MOR202 is a mAb developed using MorphoSys’ HuCAL antibody technology used for targeting CD38 cells present on the surface of multiple myeloma cells

Click here to read full press release/ article | Ref: PRNewswire | Image: Behance

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post